Key facts
- Perceive Pharma’s last known valuation is $50.0M (Feb 2025).
- It has raised $19.5M; the latest was Early Stage VC ($15.0M) in Feb 2025.
- Notable investors include GV, Catalio Capital Management, Johnson & Johnson JJDC, Deerfield Management, Braidwell — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Perceive Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Perceive Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Perceive Pharma
Developer of small molecule neuroprotective therapeutics designed for targeting glaucoma and other ophthalmic diseases. The company's platform leverages retina cell screening to identify neuroprotective biological pathways, enabling healthcare professionals to offer innovative treatments for vision-related neurodegenerative conditions, improving patient outcomes in the ophthalmic space.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Ownership
- Privately Held (backing)
Perceive Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Perceive Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Perceive Pharma in its N-PORT filings yet. We sweep new filings monthly.